These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 20501450)
1. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450 [TBL] [Abstract][Full Text] [Related]
2. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Anatelli F; Chuang ST; Yang XJ; Wang HL Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090 [TBL] [Abstract][Full Text] [Related]
3. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164 [TBL] [Abstract][Full Text] [Related]
5. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409 [TBL] [Abstract][Full Text] [Related]
6. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma. Honsová E; Lodererová A; Franková S; Oliverius M; Trunecka P Cas Lek Cesk; 2011; 150(1):37-40. PubMed ID: 21400962 [TBL] [Abstract][Full Text] [Related]
7. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053 [TBL] [Abstract][Full Text] [Related]
8. Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Longerich T; Haller MT; Mogler C; Aulmann S; Lohmann V; Schirmacher P; Brand K Pathol Res Pract; 2011 Jan; 207(1):8-14. PubMed ID: 20971570 [TBL] [Abstract][Full Text] [Related]
9. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806 [TBL] [Abstract][Full Text] [Related]
10. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Nassar A; Cohen C; Siddiqui MT Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109 [TBL] [Abstract][Full Text] [Related]
11. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914 [TBL] [Abstract][Full Text] [Related]
12. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells]. Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080 [TBL] [Abstract][Full Text] [Related]
13. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081 [TBL] [Abstract][Full Text] [Related]
14. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma]. Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223 [TBL] [Abstract][Full Text] [Related]
15. Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Nouso K; Urabe Y; Higashi T; Nakatsukasa H; Hino N; Ashida K; Kinugasa N; Yoshida K; Uematsu S; Tsuji T Cancer; 1996 Jul; 78(2):232-36. PubMed ID: 8673997 [TBL] [Abstract][Full Text] [Related]
16. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389 [TBL] [Abstract][Full Text] [Related]
17. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153 [TBL] [Abstract][Full Text] [Related]
18. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Kandil DH; Cooper K Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373 [TBL] [Abstract][Full Text] [Related]
19. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925 [TBL] [Abstract][Full Text] [Related]
20. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis]. Tátrai P Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]